CA2965729A1 - Enhancer of zeste homolog 2 inhibitors - Google Patents
Enhancer of zeste homolog 2 inhibitors Download PDFInfo
- Publication number
- CA2965729A1 CA2965729A1 CA2965729A CA2965729A CA2965729A1 CA 2965729 A1 CA2965729 A1 CA 2965729A1 CA 2965729 A CA2965729 A CA 2965729A CA 2965729 A CA2965729 A CA 2965729A CA 2965729 A1 CA2965729 A1 CA 2965729A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- oxo
- dihydropyridin
- piperidin
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 **(CC1)CC*1=*(*)c1c(*)c(C(N(*)CC2=C(*)C=C(*)NC2=O)=O)c(*)[s]1 Chemical compound **(CC1)CC*1=*(*)c1c(*)c(C(N(*)CC2=C(*)C=C(*)NC2=O)=O)c(*)[s]1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462069438P | 2014-10-28 | 2014-10-28 | |
| US62/069,438 | 2014-10-28 | ||
| US201462075596P | 2014-11-05 | 2014-11-05 | |
| US62/075,596 | 2014-11-05 | ||
| PCT/EP2015/075009 WO2016066697A1 (en) | 2014-10-28 | 2015-10-28 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2965729A1 true CA2965729A1 (en) | 2016-05-06 |
Family
ID=54360465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2965729A Abandoned CA2965729A1 (en) | 2014-10-28 | 2015-10-28 | Enhancer of zeste homolog 2 inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170334891A1 (enExample) |
| EP (1) | EP3212639A1 (enExample) |
| JP (1) | JP6571180B2 (enExample) |
| KR (1) | KR20170068603A (enExample) |
| CN (1) | CN107148419A (enExample) |
| AU (1) | AU2015340614B2 (enExample) |
| BR (1) | BR112017008840A2 (enExample) |
| CA (1) | CA2965729A1 (enExample) |
| MA (1) | MA40848A (enExample) |
| RU (1) | RU2017118165A (enExample) |
| WO (1) | WO2016066697A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| CA3050221C (en) | 2017-01-19 | 2021-09-28 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of htlv-1-associated myelopathy |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| FI4043466T3 (fi) | 2018-01-31 | 2024-10-30 | Mirati Therapeutics Inc | Prc2:n estäjiä |
| WO2019226491A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| WO2020247475A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| KR20220041130A (ko) * | 2019-07-24 | 2022-03-31 | 콘스텔레이션 파마슈티칼스, 인크. | 암 치료를 위한 병용 요법에서의 ezh2 억제 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| IL316421A (en) | 2022-04-27 | 2024-12-01 | Daiichi Sankyo Co Ltd | Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20170736T1 (hr) * | 2010-05-07 | 2017-07-28 | Glaxosmithkline Llc | Indoli |
| JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| EP2773754B1 (en) * | 2011-11-04 | 2016-08-03 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compounds for use in the treatment of T-cell mediated diseases |
| EP2812001B1 (en) * | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CA2910873A1 (en) * | 2013-04-30 | 2014-11-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| JP2016523955A (ja) * | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
-
2015
- 2015-10-28 KR KR1020177014034A patent/KR20170068603A/ko not_active Withdrawn
- 2015-10-28 BR BR112017008840A patent/BR112017008840A2/pt not_active Application Discontinuation
- 2015-10-28 RU RU2017118165A patent/RU2017118165A/ru not_active Application Discontinuation
- 2015-10-28 MA MA040848A patent/MA40848A/fr unknown
- 2015-10-28 WO PCT/EP2015/075009 patent/WO2016066697A1/en not_active Ceased
- 2015-10-28 CA CA2965729A patent/CA2965729A1/en not_active Abandoned
- 2015-10-28 AU AU2015340614A patent/AU2015340614B2/en not_active Ceased
- 2015-10-28 CN CN201580058856.7A patent/CN107148419A/zh active Pending
- 2015-10-28 EP EP15786958.7A patent/EP3212639A1/en not_active Withdrawn
- 2015-10-28 US US15/522,373 patent/US20170334891A1/en not_active Abandoned
- 2015-10-28 JP JP2017522890A patent/JP6571180B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017532360A (ja) | 2017-11-02 |
| RU2017118165A3 (enExample) | 2018-12-10 |
| WO2016066697A1 (en) | 2016-05-06 |
| CN107148419A (zh) | 2017-09-08 |
| AU2015340614B2 (en) | 2018-07-19 |
| US20170334891A1 (en) | 2017-11-23 |
| BR112017008840A2 (pt) | 2017-12-19 |
| AU2015340614A1 (en) | 2017-05-18 |
| MA40848A (fr) | 2021-05-05 |
| JP6571180B2 (ja) | 2019-09-04 |
| EP3212639A1 (en) | 2017-09-06 |
| KR20170068603A (ko) | 2017-06-19 |
| RU2017118165A (ru) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015340614B2 (en) | Enhancer of zeste homolog 2 inhibitors | |
| US9790212B2 (en) | Enhancer of zeste homolog 2 inhibitors | |
| US9649307B2 (en) | Indoles | |
| EP2755962B1 (en) | Azaindazoles | |
| EP3019494B1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| US9382234B2 (en) | Enhancer of Zeste Homolog 2 inhibitors | |
| AU2016286537B2 (en) | Enhancer of Zeste Homolog 2 inhibitors | |
| EP3452483B1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| CA2914414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| HK1261043B (en) | Enhancer of zeste homolog 2 inhibitors | |
| HK1261043A1 (en) | Enhancer of zeste homolog 2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220118 |
|
| FZDE | Discontinued |
Effective date: 20220118 |